C4 Therapeutics, Inc. (CCCC)
Data as of , from SEC Form 4 filings.
See up to 3 months of CCCC. The 7-day demo opens the 1M and 3M ranges and puts CCCC on your watchlist.
Start 7-day demoLatest CCCC insider trades
- Leonard Reyno - OfficerOpen-market sale$22K
- Kenneth Carl Anderson - DirectorGrant or award$11K
Donna Roy Grogan - Director
About C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
- WATERTOWN, MA
- 104
- 2020
- XNAS
CCCC Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 2 | 8,280 | |
| Option exercise | 1 | 6,250 | |
| Tax withholding / forfeiture | 1 | 2,775 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CCCC insider transactions (Form 4)
2241 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Kenneth Carl Anderson - Director | Grant or award | Common Stock | 7,616 | $1.51 | $12K | |
| Donna Roy Grogan - Director | Grant or award | Common Stock | 9,609 | $1.51 | $15K | |
| Steven L. Hoerter - Director | Grant or award | Stock Option (Right to Buy) | 65,000 | $0.00 | - | |
| Scott N. Boyle - Officer | Option exercise | Common Stock | 3,750 | - | - | |
| Scott N. Boyle - Officer | Tax withholding / forfeiture | Common Stock | 1,102 | $6.04 | $7K | |
| Scott N. Boyle - Officer | Option exercise | Performance Restricted Stock Units | 3,750 | $0.00 | - | |
| Kendra Adams - Officer | Option exercise | Common Stock | 3,750 | - | - | |
| Kendra Adams - Officer | Tax withholding / forfeiture | Common Stock | 1,102 | $6.04 | $7K | |
| Kendra Adams - Officer | Option exercise | Performance Restricted Stock Units | 3,750 | $0.00 | - | |
| Kelly Schick - Officer | Option exercise | Common Stock | 3,750 | - | - | |
| Kelly Schick - Officer | Tax withholding / forfeiture | Common Stock | 1,102 | $6.04 | $7K | |
| Kelly Schick - Officer | Option exercise | Performance Restricted Stock Units | 3,750 | $0.00 | - | |
| Jolie Siegel - Officer | Option exercise | Common Stock | 3,750 | - | - | |
| Jolie Siegel - Officer | Tax withholding / forfeiture | Common Stock | 1,102 | $6.04 | $7K | |
| Jolie Siegel - Officer | Option exercise | Performance Restricted Stock Units | 3,750 | $0.00 | - | |
| Andrew Hirsch - Officer | Option exercise | Common Stock | 12,500 | - | - | |
| Andrew Hirsch - Officer | Tax withholding / forfeiture | Common Stock | 5,550 | $6.04 | $34K | |
| Andrew Hirsch - Officer | Option exercise | Performance Restricted Stock Units | 12,500 | $0.00 | - | |
| Paige Mahaney - Officer | Grant or award | Common Stock | 76,800 | $0.00 | - | |
| Paige Mahaney - Officer | Grant or award | Stock Option (Right to Buy) | 345,600 | $0.00 | - | |
| Donna Roy Grogan - Director | Grant or award | Common Stock | 2,474 | $5.56 | $14K | |
| Kenneth Carl Anderson - Director | Grant or award | Common Stock | 2,023 | $5.56 | $11K |
Recent CCCC Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Mark Mossler | Officer | 4,139 | $18K | View on EDGAR | |
| JAY GELDMACHER | Former REZI CEO | 82,563 | $1.90M |
CCCC insider trading FAQ
What is the latest insider trade for CCCC?
C4 Therapeutics, Inc. (CCCC) had 3 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for CCCC runs to 41 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CCCC stock?
No insider purchases of CCCC were filed in the last 90 days.
How many insiders are selling CCCC stock?
No insider sales of CCCC were filed in the last 90 days. 1 sale is on record for this company.
Where can I see CCCC SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CCCC Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Kenneth Carl Anderson view on EDGAR
- - Donna Roy Grogan view on EDGAR
- - Kendra Adams view on EDGAR
- - Leonard Reyno view on EDGAR
- - Kenneth Carl Anderson view on EDGAR
- - Donna Roy Grogan view on EDGAR
- - Owen Hughes view on EDGAR
- - Steven L. Hoerter view on EDGAR
- - Utpal Koppikar view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CCCC's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CCCC with a 7-day demo
- CCCC on your watchlist
- Every CCCC Form 4 filing on record
- Up to 3 months of CCCC price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
